BidaskClub Downgrades Supernus Pharmaceuticals (SUPN) to Hold

BidaskClub cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a report issued on Saturday morning.

Other analysts have also issued research reports about the company. Jefferies Financial Group upped their price objective on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a buy rating in a research note on Thursday. Cantor Fitzgerald set a $56.00 target price on Supernus Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday. ValuEngine lowered Supernus Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Friday, June 8th. Stifel Nicolaus increased their target price on Supernus Pharmaceuticals from $50.00 to $60.00 and gave the stock a buy rating in a research note on Friday, May 25th. Finally, Piper Jaffray Companies reiterated a hold rating and set a $46.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, July 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $54.09.

NASDAQ SUPN traded down $1.95 during trading hours on Friday, hitting $46.15. 1,498,373 shares of the company traded hands, compared to its average volume of 732,104. The company has a debt-to-equity ratio of 0.82, a quick ratio of 4.74 and a current ratio of 2.74. The stock has a market capitalization of $2.49 billion, a PE ratio of 36.63 and a beta of 0.97. Supernus Pharmaceuticals has a twelve month low of $33.30 and a twelve month high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.14. The firm had revenue of $99.54 million for the quarter, compared to analyst estimates of $101.01 million. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. research analysts forecast that Supernus Pharmaceuticals will post 1.91 EPS for the current year.

In other news, CFO Gregory S. Patrick sold 35,000 shares of the stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $56.63, for a total transaction of $1,982,050.00. Following the transaction, the chief financial officer now owns 75,975 shares in the company, valued at $4,302,464.25. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Stefan K.F. Schwabe sold 60,000 shares of the stock in a transaction that occurred on Monday, June 18th. The stock was sold at an average price of $54.39, for a total value of $3,263,400.00. Following the transaction, the vice president now owns 21,967 shares in the company, valued at approximately $1,194,785.13. The disclosure for this sale can be found here. In the last quarter, insiders have sold 117,868 shares of company stock worth $6,600,620. 6.20% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in SUPN. NumerixS Investment Technologies Inc bought a new position in Supernus Pharmaceuticals during the 2nd quarter worth $204,000. Everence Capital Management Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $205,000. Cim LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $207,000. Diversified Trust Co acquired a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at $211,000. Finally, Wesbanco Bank Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at $229,000. Institutional investors own 98.01% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Story: Google Finance Portfolio Workaround

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply